Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells

Journal of Immunological Methods

Volumn 248, Issue 1-2, 2001, Pages 113-123

  Sundarapandiyan, Karuna ^a   Keler, Tibor ^a   Behnke, Detlev ^b   Engert, Andreas ^c   Barth, Stefan ^c   Matthey, Baerbel ^c   Deo, Yashwant M ^a   Graziano, Robert F ^a  

^a MEDAREX INC   (United States)

^b MEDAC GMBH   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

ADCC; Fc receptor; Hodgkin's disease; Phagocytosis

Indexed keywords

ANTIBODY; ANTIBODY A 77; ANTIBODY CD 64; ANTIBODY CD 89; ANTIBODY CD30; ANTIBODY H 22; ANTIBODY KI 4; IMMUNOGLOBULIN F(AB) FRAGMENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEDIATED CYTOTOXICITY; EFFECTOR CELL; HODGKIN DISEASE; IN VITRO STUDY; MACROPHAGE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RECEPTOR AFFINITY; TARGET CELL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; ANTIGENS, CD30; HODGKIN DISEASE; HUMANS; MICE; PHAGOCYTOSIS; RECEPTORS, FC; RECEPTORS, IGG; TUMOR CELLS, CULTURED;

EID: 0035251649     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00347-1     Document Type: Article

References (35)

1. Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies
2. Bispecific molecules directed to the Fc receptor for IgA (FcαRI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood
3. Hodgkin's disease: Establishment and characterization of four in vitro cell lines
4. Bispecific-armed, interferon γ-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma
5. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma
6. High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice
7. 2 antibody containing thioether-linked Fab′ fragments
8. Fully human single-chain bispecific antibodies directed to the Fc receptor for IgA (FcαRI, CD89) and tumor antigens promotes cell-mediated cytotoxicity of tumor targets
9. Construction and characterization of a humanized anti-γ-Ig receptor type I (FcγRI) monoclonal antibody
10. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
11. Pathophysiology of Hodgkin's disease: Functional and molecular aspects
12. Monoclonal antibodies that bind to distinct epitopes of FcγR are able to trigger receptor function
13. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines
14. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4)
15. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay
16. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells
17. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fcγ receptor type I-expressing effector cells
18. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA′) is a potent immunotoxin against a Hodgkin-derived cell line
19. Antigen-specific human antibodies from mice comprising four distinct genetic modifications
20. Spontaneous aggregation as a mechanism of human monocyte purification
21. Molecular heterogenicity of Fcα receptor detected by receptor-specific monoclonal antibodies
22. Structure and function of human IgA Fc receptors (FcαR)
23. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulated factor
24. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome
25. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis
26. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma
27. Hodgkin's disease: A disorder of dysregulated cellular cross-talk
28. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody
29. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen
30. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin
31. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells
32. Bispecific antibody-mediated destruction of prostate cancer cells
33. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice
34. FcαRI as a novel trigger molecule for bispecific antibody therapy
35. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells